Research Scientist I
Acuitas Therapeutics, Canada
Mitchell Beattie, BSc is a research scientist at Acuitas Therapeutics, a biotechnology company based in Vancouver, British Columbia, Canada. He received a Bachelor of Science degree in Biochemistry and Molecular Biology from the University of British Columbia in 2016 and has done research and development work in the BC biotechnology sector for almost 10 years. He has co-authored a number of publications in the RNA-LNP field and contributed to the development of the lipid nanoparticle formulation used in Pfizer-BioNTech’s Comirnaty Covid-19 vaccine.
